Recherche Recherche de structure
wx_img
Inquiry Form
  1. Home
  2. Abemaciclib

Abemaciclib

Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

4-bromo-2,6-difluorobenzenamine
4-bromo-2,6-difluorobenzenamine
CM101602
67567-26-4
6-bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
6-bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
CM130252
1231930-33-8
2,4-Dichloro-5-fluoropyrimidine
2,4-Dichloro-5-fluoropyrimidine
CM219871
2927-71-1
6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
CM161840
1231930-42-9
2-Amino-5-formylpyridine
2-Amino-5-formylpyridine
CM174092
69879-22-7
5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-amine
5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-amine
CM169616
1180132-17-5